Ixazomib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 2.3 mg, 3 mg, 4 mg
Reference Brands: Ninlaro® (EU & US)
Category:
Oncology Cancer Care
Ixazomib Capsules (brand name Ninlaro®) are oral proteasome inhibitors used in multiple myeloma treatment. Available in 2.3 mg, 3 mg, and 4 mg strengths, they are approved in the US and EU and manufactured under GMP standards, offering a convenient and reliable oncology option for B2B pharma partners.
Ixazomib is available in Capsules
and strengths such as 2.3 mg, 3 mg, 4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ixazomib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ixazomib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ixazomib Capsules, marketed under the brand name Ninlaro®, are a novel oral proteasome inhibitor used in combination therapies for multiple myeloma in patients who have received at least one prior treatment. Ixazomib works by blocking the 20S proteasome, disrupting protein homeostasis in cancer cells and promoting apoptosis. Available in 2.3 mg, 3 mg, and 4 mg capsule strengths, it provides a convenient oral option for patients and physicians. Manufactured under GMP-compliant facilities, Ixazomib is approved in both the US and EU markets, making it an attractive and effective B2B oncology solution for global pharmaceutical supply chains.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing